Table 1 Summary of study type and patient characteristics in SLR-identified publications (n = 87) by TNFi treatment
| Â | Adalimumab | Etanercept | Golimumab | Infliximab |
|---|---|---|---|---|
Study type, n | ||||
 Total | 26 | 67 | 7 | 14 |
 Observational | 22 | 55 | 5 | 12 |
 RCT | 3 | 8 | 1 | 1 |
 nRCT | 1 | 4 | 1 | 1 |
JIA category, n | ||||
 Multiple | 9 | 26 | 3 | 5 |
 PA | 3 | 11 | 2 | 1 |
 sJIA | 1 | 5 | 0 | 0 |
 nsJIA | 1 | 3 | 0 | 0 |
 ERA | 1 | 7 | 0 | 0 |
Age at treatment start, years | ||||
 Mean | 3.0–17.5 | 3.1–16.2 | 11.1–13.6 | 10.6–21.8 |
 Median | 4.9–13.9 | 10.0–21.0 | 13.0* | 11.9* |
Follow-up duration | ||||
 Mean, years | 3.58–3.96 | 0.5–6.8 | 1.0* | 0 |
 Median, months | 51.0–53.7 | 12.0–35.6 | 0 | 51.0–53.7 |
 Range, months | 3–120 | 3–216 | 7–40 | 12–120 |
 Person-years | 14–1,855 | 3–6,726 | 3.5–326 | 26–591 |